FEC及TC方案在乳腺癌新辅助化疗中的疗效及经济性研究

Research on efficacy and economy of FEC and TC scheme in neoadjuvant chemotherapy for breast cancer

目的探讨FEC及TC方案在乳腺癌新辅助化疗中的疗效及经济性。方法对哈尔滨医科大学附属第一医院收治的90例乳腺癌患者资料进行回顾性分析,根据治疗方案不同分为FEC组(F氟尿嘧啶、E表柔比星、C环磷酰胺)和TC组(T多西他赛、C环磷酰胺),比较两组的疗效及经济性。结果 FEC组的有效率为46.7%,TC组的有效率为44.4%,两组差异无统计学意义(P>0.05);FEC组和TC组的成本分别为755.97元、2 622.91元,两组差异有统计学意义(P<0.05)。结论 FEC及TC方案在乳腺癌新辅助化疗中的疗效相当,但FEC组的治疗成本相对较少,值得推广。

Objective To explore the curative effect and economy of FE-C and TC schemes in neoadjuvant chemotherapy for breast cancer.Methods The data in 90 cases of breast cancer in our hospital were retrospectively analyzed.The patients were divided into the FEC group（fluorouracil,epirubicin and cyclophosphamide）and TC（docetaxel and cyclophosphamide）group according to the different treatment schemes.Then curative effect and economy were compared between the two groups.Results The effective rate of the FEC group was 46.7%,which of TC group was 44.4%（P〉0.05）;the costs of the FEC group and TC group were 755.97 Yuan and 2 622.91 Yuan respectively（P〈0.05）.Conclusion Adopting the FEC and TC schemes in neoadjuvant chemotherapy of breast cancer have the same effect,but the curative cost of the FEC group is relatively small and is worth promotion.